在细胞遗传学和分子水平上,早期T细胞前体ALL(ETP-ALL)与急性髓细胞白血病(AML)或混合型ALL-AML相类似,与预后不良有关,可能受益于AML治疗(低甲基化药物和维奈克拉),并在CR时受益于allo-SCT。迄今为止,缺乏有效的抗T细胞靶向疗法,免疫...
Leukemia Research is an international journal which brings comprehensive and current information to all health care professionals involved in basic...Eric Feldman
[3] Mrózek K, Harper DP, Aplan PD. Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009 Oct;23(5):991-1010, v. [4] Jabbour E, Short NJ, Jain N, et al. The...
在急性白血病(AML 與ALL) 與慢性骨髓系白血病(芽細胞危象期) 之Ku 70 與Ku 80 表現均呈現顯著關聯性(p 值小於0.05).由於Ku 蛋白質與其RNA 量在急性白Ku 蛋白質與p-gp 或早期標記(CD34,HLA-DR,CD7) 並無顯著關聯性.BCR-ABL 陽性K562 細胞經proteasome 抑制劑(lactacystin 或LLnl) 處理後,Ku 蛋白質表現...
Therefore, the European LeukemiaNet MRD Working Party recommends using 0.1% as the threshold to distinguish MRD-positive from MRD-negative patients with AML [49]. A cutoff of 0.01% can be achieved in B-ALL and T-ALL, which was accepted by most researchers [22,47]. Currently, MFC monitorin...
The outcome of allogeneic HSCT in older AML patients is determined by disease biology and not by the donor type: an analysis of 96 allografted AML patients ≥ 50 years from the Czech acute leukaemia clinical register (alert). Neoplasma. 2013;60:576–83. Article CAS Google Scholar ...
目的研究表达淋巴系抗原的急性髓性白血病(Ly+ AML)、表达髓系抗原的急性淋巴细胞白血病(My+ALIL)、急性髓性白血病(AMIL)、急性淋巴细胞白血病(ALL)和急性双表型白血病(BAL)的预后。方法采用 CD45/SSC 双参数散点图设门,应用三色流式细胞术,对197例急性白血病(AL)初诊患者骨髓标本进行免疫分型,采用白血病免疫关键...
CALLA reacts with leukemic cells of 110 of 134 patients (82%) with non-T-cell ALL; 1 of 71 (1%) patients with acute myelogenous leukemia (AML); 2 of 7 patients (29%) with chronic myelogenous leukemia in blast crisis; 7 of 92 patients (8%) with other hematologic malignancies; and ...
Thymidine kinase 1 – A prognostic and diagnostic indicator in ALL and AML patients. K L O’Neill,F Zhang,H Li,D G Fuja,B K Murray. Leukemia . 2007O'Neill KL, Zhang F, Li H, Fuja DG and Murray BK: Thymidine kinase 1-a prognostic and diagnostic indicator in ALL and AML patients...
[6] Jabbour E, Short NJ, Jain N, et al. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. J Hematol Oncol. 2023;16(1):22. Published 2023 Mar 16. [7] Gong, et...